RxDoctor Payments Data

Michelle Uttaburanont, MD

Internal Medicine · Temecula, CANPI 1528297918

Payments from drug & device makers

$3,181in general payments, 2019–2025

Across 152 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$498
  • GSK$398
  • Novo Nordisk$303
  • Lilly USA, LLC$277
  • Pfizer$186
  • Abbott$170
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,181 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$83,926
Medicare patients
359
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$148,499
JardianceEmpagliflozin95$130,378
OzempicSemaglutide101$96,810
XareltoRivaroxaban25$34,376
FarxigaDapagliflozin Propanediol27$26,419
JanuviaSitagliptin Phosphate12$20,174
ProliaDenosumab11$17,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,733
Fenofibrate29$11,487
Atorvastatin Calcium764$7,896
Repatha PushtronexEvolocumab12$7,048
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,197
Levothyroxine Sodium487$5,020
SynthroidLevothyroxine Sodium66$4,134
Losartan Potassium388$3,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$148,499136 claims
Boehringer IngelheimJardiance$140$130,37895 claims
Novo NordiskOzempic$303$96,810101 claims
Johnson & JohnsonXarelto$143$34,37625 claims
AstraZenecaFarxiga, Symbicort$498$29,63141 claims
MerckJanuvia$148$20,17412 claims
AmgenProlia$60$17,01511 claims
GSKTrelegy Ellipta$398$12,73321 claims
AbbVieSynthroid$128$4,13466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →